| Literature DB >> 35013721 |
Alireza Nikzad Jamnani1, Mahbobeh Montazeri2, Maryam Mirzakhani3, Mahmood Moosazadeh4, Mohammad Haghighi5.
Abstract
Patients with confirmed SARS-CoV-2 are principally at risk of emerging superinfections, particularly those caused by Gram-negative bacteria. Therefore, in this retrospective cohort study, we investigated the presence of bacteria in endotracheal aspirate samples in severe COVID-19 patients under mechanical ventilation between 20 February 2020 and 21 September 2020 in Mazandaran Heart Center Hospital, Iran. Outcomes were compared between ICU patients with confirmed SARS-CoV-2 (corona group) and those who suffer from other disease (non-corona group). Out of 38 subjects who met the diagnostic criteria for ventilator-associated pneumonia (VAP) in ICU, 22 and 16 patients in corona and non-corona groups, respectively, were enrolled in the study. Hospital length of stay in 27% of case in corona group was > 10 days. Also, SOFA score was > 10 in 64% and 25% of corona and non-corona groups, respectively (P < 0.05). Moreover, the number of death was significantly higher among corona patients (45%) than non-corona group (6%) in ICU (P < 0.05). Acinetobacter spp. were the most common bacteria in nine corona patients (41%) that were 100% resistant to amikacin, gentamycin, cefixime, and imipenem antibiotics. The prevalence of antibiotic resistance among pathogens isolated from patients with COVID-19 under mechanical ventilation in ICU highlighted the importance of preventing coinfections caused by this pathogen, suggesting an essential standardized approach to antibiotic stewardship in patients with COVID-19 for successful treatment.Entities:
Keywords: Antibiotic resistance; Bacterial coinfection; SARS-CoV-2; Ventilator-associated pneumonia
Year: 2022 PMID: 35013721 PMCID: PMC8733817 DOI: 10.1007/s42399-021-01114-9
Source DB: PubMed Journal: SN Compr Clin Med ISSN: 2523-8973
Comparison of demographic features, risk factors, and clinical characteristics in corona and non-corona groups (data are the number)
| Variables | Corona groupa ( | Non-corona groupb ( | |
|---|---|---|---|
| Gender | |||
| Male | 7 (32) | 3 (19) | 0.469 |
| Female | 15 (68) | 13 (81) | |
| Age group (years) | |||
| 40–50 | 2 (9) | 1 (6) | |
| 50–60 | 3 (14) | 3 (19) | 0.370 |
| 60–70 | 6 (27) | 4 (25) | |
| > 70 | 11 (50) | 8 (50) | |
| Length of stay (days) | |||
| < 10 | 16 (73) | 8 (50) | 0.187 |
| > 10 | 6 (27) | 8 (50) | |
| Positive PCR | 9 (41) | - | - |
| SOFA | |||
| < 10 | 8 (36) | 12 (75) | 0.040 |
| 10–20 | 12 (54) | 4 (25) | |
| > 20 | 2 (10) | ||
| Final outcome | |||
| Recovery | 12 (55) | 15 (94) | 0.012 |
| Death | 10 (45) | 1 (6) | |
aAll patients with confirmed SARS-CoV-2 infection
bAll patients suffering from other disease
Resistance of bacteria to different classes of antibiotics associated to VAP in corona group patients
| Antibiotic | Microorganism | ||||||
|---|---|---|---|---|---|---|---|
| - | Others* | ||||||
| Ampicillin | NT | NT | NT | NT | 100 | 100 | NT |
| Penicillin G | NT | NT | NT | NT | 100 | 100 | NT |
| Cephalithin | NT | NT | NT | NT | NT | 100 | NT |
| Clindamycin | NT | NT | NT | NT | 0 | 100 | NT |
| Oxacillin | NT | NT | NT | NT | 0 | 100 | NT |
| Vancomycin | NT | NT | NT | NT | 0 | 25 | NT |
| Cefatriaxon | 50 | 75 | NT | 0 | NT | NT | NT |
| Co-trimaazol | 50 | 100 | 100 | 100 | NT | NT | NT |
| Cefixime | 100 | 100 | 100 | 100 | NT | NT | NT |
| Amikacin | 100 | 25 | 100 | 0 | NT | NT | NT |
| Gentamycin | 100 | 25 | 100 | 0 | NT | NT | NT |
| Nitrofurantein | 100 | 25 | NT | 0 | NT | NT | NT |
| Ciprofloxacin | 50 | 50 | 100 | 0 | NT | NT | NT |
| Colistin | 50 | 25 | 0 | NT | NT | NT | NT |
| Ceftazidime | 50 | NT | 100 | 0 | NT | NT | NT |
| Imipenem | 100 | NT | NT | NT | NT | NT | NT |
Candida spp. 4 (18.2), diphtheroid 3 (13.6); NT not tested